Abbott Q1 Diagnostics Revenues More Than Double on
Post# of 11802
(Total Views: 456)
Posted On: 04/22/2021 11:38:39 AM
Abbott Q1 Diagnostics Revenues More Than Double on COVID-19 Testing
https://www.360dx.com/business-news/abbott-q1...19-testing
Demand for rapid and laboratory-based SARS-CoV-2 tests drove the diagnostic segment's strong growth, the company said in a statement. COVID-19 testing sales were $2.2 billion for the quarter, with $1.8 billion in sales from Abbott's BinaxNow, Panbio, and ID Now rapid tests.
What a market! I hope DECN gets the stamp in Europe soon and starts to grind their teeth into the market.
Covid in India:
https://www.bbc.com/news/world-asia-india-56826645
https://www.360dx.com/business-news/abbott-q1...19-testing
Demand for rapid and laboratory-based SARS-CoV-2 tests drove the diagnostic segment's strong growth, the company said in a statement. COVID-19 testing sales were $2.2 billion for the quarter, with $1.8 billion in sales from Abbott's BinaxNow, Panbio, and ID Now rapid tests.
What a market! I hope DECN gets the stamp in Europe soon and starts to grind their teeth into the market.
Covid in India:
https://www.bbc.com/news/world-asia-india-56826645
(5)
(0)Decision Diagnostics Corp (DECN) Stock Research Links
Scroll down for more posts ▼